CAS: 498-62-4; Thiophene-3-Carbaldehyde

上下游产品

CAS号71637-34-8 3-噻吩甲醇 | CAS号872-31-1 3-溴噻吩 | CAS号201230-82-2 carbon monoxide | CAS号68-12-2 N,N-二甲基甲酰胺 | CAS号88-13-1 3-噻吩甲酸 | CAS号113772-16-0 2,5-二氢噻吩-3-甲醛 | CAS号50978-45-5 N-甲酰基糖精 | CAS号1468-83-3 3-乙酰基噻吩 | CAS号35022-11-8 3-styryl-thiophene | CAS号10486-61-0 3-碘噻吩 | CAS号110143-52-7 3-(2-硝基乙烯基)噻吩 | CAS号105124-99-0 4-bromo-2-thiop... | CAS号32281-36-0 苯并[1,2-b:4,5-b'... | CAS号3199-44-8 噻吩-3-甲醛乙缩醛二乙醇 | CAS号59311-67-0 3-氨乙基噻吩 | CAS号36646-69-2 CYCLOHEXYL 3-TH... | CAS号389-58-2 环戊联噻吩 | CAS号5650-51-1 5,6-二氢环戊并[b]噻吩-4-酮 | CAS号56182-43-5 2-溴噻吩-3-腈 | CAS号149977-36-6 3-(2-nitroprop-...

3-甲基噻吩置于n-氯代丁二酰亚胺,偶氮二异丁腈,N-甲基吗啉氧化物体系中,用 乙酸乙酯 作为反应溶剂,化学反应 8.0H,反应生成 3-噻吩甲醛
参考文献:一种3-噻吩甲醛的制备方法
标题:一种3-噻吩甲醛的制备方法
摘要:本发明公开了一种3‑噻吩甲醛的制备方法,包括:将3‑甲基噻吩和有机溶剂混合并加热至第一温度,保持所述第一温度不变,分别加入偶氮二异丁氰和n‑卤代丁二酰亚胺,在所述第一温度下保温一段时间后降温,然后过滤,得到3‑卤代甲基噻吩的混合溶液;无需任何处理,即向3‑卤代甲基噻吩的混合溶液中加入n‑甲基吗啉‑n‑氧化物,加热至第二温度后,经降温,水洗,脱溶得到粗品,进一步精馏,即制得3‑噻吩甲醛纯品.本发明克服了现有合成方法中选择性差,收率低等问题,是一种高选择性,高收率,在温和反应条件下即可合成3‑噻吩甲醛的方法;并且本发明的制备方法操作简单,无刺激性,原料易得,节约了操作成本和原料成本,适用于工业化生产3‑噻吩甲醛.

专利信息

专利号:US-2022356139-A1
优先权日:2019-09-03
标 题:Synthesis of deuterated aldehydes
发明人：WANG WEI
权利人:ARIZONA BOARD OF REGENTS ON BEHALF OF ATHE UNIV OF ARIZONA
摘要:Described are methods for preparing a deuterated aldehyde using N-heterocyclic carbene catalysts in a solvent comprising D 2 O. The methods may be used to convert a wide variety of aldehydes (e.g., aryl, alkyl, or alkenyl aldehydes) to C-1 deuterated aldehydes under mild reaction conditions without functionality manipulation.

专利号:US-6225329-B1
优先权日:1998-03-12
标 题 :Modulators of protein tyrosine phosphatases (PTPases)
发明人：RICHTER LUTZ STEFAN; ANDERSEN HENRIK SUNE; VAGNER JOSEF; JEPPESEN CLAUS BEKKER; MOELLER NIELS PETER HUNDAHL; BRANNER SVEN; SU JING; BAKIR FARID; JUDGE LUKE MILBURN
权利人:NOVO NORDISK AS
摘要:The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like, n wherein A, R 1 , R 2 , R 3 , R 4 , R 16 and R 17 are as defined in the specification. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

专利号:US-6121054-A
优先权日:1997-11-19
标 题 :Method for separation of liquid and solid phases for solid phase organic syntheses
发明人：LEBL MICHAL
权利人:TREGA BIOSCIENCES INC
摘要:A simple, efficient apparatus and method for separation of solid and liquid phases useful in methods of high-throughput combinatorial organic synthesis of large libraries or megaarrays of organic compounds is disclosed. The apparatus and method are useful, whether as part of an automated, robotic or manual system for combinatorial organic synthesis. In a preferred embodiment, an apparatus and method of removal of liquid phase from solid phase compatible with microtiter plate type array(s) of reaction vessels is disclosed.

专利号:US-7423154-B2
优先权日:2001-03-07
标 题 :Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates
发明人：BROWN WILLIAM; PLOBECK NIKLAS
权利人:ASTRAZENECA AB
摘要:An asymmetric synthesis of diarylmethylpiperazines is described. The synthetic route enables preparation of a variety of enatiomerically pure amines with different N-alkyl groups. The invention includes an asymmetric addition of organometallic compounds to chiral sulfinimine to give adducts in predominantly one diastereomer can subsequently be transferred into pure enantiomers of by cleavage of the chiral auxilliary which is followed by synthesis of the piperazine ring by alkylation procedures.

专利号:WO-9946236-A1
优先权日:1998-03-12
标题 :Modulators of protein tyrosine phosphatases (ptpases)
发明人：RICHTER LUTZ STEFAN; ANDERSEN HENRIK SUNE; VAGNER JOSEF; JEPPESEN CLAUS BEKKER; MOELLER NIELS PETER HUNDAHL; BRANNER SVEN; SU JING; BAKIR FARID; JUDGE LUKE MILBURN
权利人:NOVO NORDISK AS; ONTOGEN CORP
摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

专利号:EP-1062199-A1
优先权日:1998-03-12
标题 :Modulators of protein tyrosine phosphatases (ptpases)
发明人：RICHTER LUTZ STEFAN; ANDERSEN HENRIK SUNE; VAGNER JOSEF; JEPPESEN CLAUS BEKKER; MOLLER NIELS PETER HUNDAHL; BRANNER SVEN; SU JING; BAKIR FARID; JUDGE LUKE MILBURN
权利人:NOVO NORDISK AS; ONTOGEN CORP
摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.